Danaher Corp. stock underperforms Tuesday when compared to competitors despite daily gains
Shares of Danaher Corp. (DHR) increased by 2.66% on Tuesday, reaching $188.41, breaking a two-day losing streak. This occurred during a mixed trading session where the Dow Jones Industrial Average rose and the S&P 500 Index fell. Despite its daily gain, the stock underperformed compared to some competitors.
Wolfe Research Downgrades Danaher Corporation (DHR)
Wolfe Research downgraded Danaher Corporation (DHR) to Peer Perform on June 1st, citing
Wolfe Research Downgrades Danaher Corporation (DHR)
Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform, citing similar growth to Thermo Fisher, which is "a little cheaper on P/E," and confusion regarding DHR's identity after the Masimo transaction. This comes despite RBC Capital resuming coverage with an Outperform rating and a $200 price target, foreseeing growth recovery driven by improvements in the bioprocess market. While DHR is a significant diagnostics stock, the article suggests certain AI stocks may offer greater upside potential with less downside risk.
Masimo Corporation stock hits 52-week high at 179.98 USD
Masimo Corporation stock has reached a 52-week high of $179.98, reflecting a 7.09% increase over the past year and significant surges in recent months. Despite trading slightly above its Fair Value according to InvestingPro, the company boasts strong financial health with a perfect Piotroski Score of 9. Recent analyst activity has focused on its acquisition by Danaher, leading to both a raised price target from Jefferies and a downgrade from Raymond James.
We Expect Veralto to Deliver Mid-Single-Digit Core Revenue Growth Through the Cycle
Morningstar anticipates Veralto (VLTO) will achieve mid-single-digit core revenue growth over the long term. The company, spun off from Danaher in 2023, operates in water quality and product quality and innovation segments, with recurring revenue making up approximately 61% of its business. This outlook comes even after Veralto raised its full-year guidance following a strong start to 2026.
Medtronic gets FDA nod for updated pulse oximetry system
Medtronic has received FDA clearance for an updated version of its Nellcor pulse oximetry system, featuring a new processor (Nell-EQ) designed to improve accuracy across diverse skin tones and patient populations. This clearance positions Medtronic competitively against Masimo and addresses concerns previously raised by the FDA regarding pulse oximeter accuracy in individuals with darker skin pigmentation. Medtronic plans a global rollout of the updated system, along with clinician education and training.
Everpure Jumps 34% in a Year: Should Investors Bet on the Stock?
Everpure (P) stock has significantly outperformed its industry and major competitors, Xylem (XYL) and Danaher (DHR), over the past year and three months. This growth is attributed to its strong subscription revenue momentum, which provides high future revenue visibility and shifts towards recurring cash flows. Despite trading at a premium valuation, Everpure's financial health, high return on equity, capital-light business model, and optimistic analyst outlook make it a compelling "Buy" for investors seeking long-term growth and shareholder value creation.
SIRI Stock Surges 5% After-Hours On S&P MidCap 400 Inclusion
Sirius XM Holdings (SIRI) saw its stock jump 5% in after-hours trading following the announcement that it will replace Masimo Corp. in the S&P MidCap 400. This inclusion, driven by Danaher Corp.'s acquisition of Masimo, is expected to prompt buying by index-tracking funds and ETFs. The move marks a significant milestone for Sirius XM, which has also seen its stock gain 34% this year due to other catalysts.
As Danaher nears Masimo deal, Sirius XM moves into S&P index
Sirius XM Holdings (SIRI) is set to join the S&P MidCap 400 index on June 11, 2026, replacing Masimo (MASI). This change is due to Danaher (DHR) acquiring Masimo, with the acquisition expected to close soon. Sirius XM will be categorized under Communication Services, while Masimo will exit from the Health Care sector.
Danaher Corp. stock (US2358511028): Diagnostics and life science group after recent earnings in focu
Danaher Corp. (US2358511028) remains a focus for investors following its latest quarterly report and 2024 outlook, which showed stabilizing demand in bioprocessing and diagnostics. The company's strategic shift towards life sciences and diagnostics, driven by its Danaher Business System and disciplined acquisitions, aims to leverage recurring revenue streams. The article highlights Danaher's core business model, key revenue drivers, and its significance for US investors tracking healthcare and research infrastructure trends.
Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis
Phenomenex Inc. has launched its new Luna Omega HILIC LC Columns, designed to improve the separation of highly polar and hydrophilic compounds. These columns are an expansion of the Luna Omega portfolio and aim to simplify HILIC method development while offering enhanced reliability and resolution. The product addresses the growing need for sensitive and consistent HILIC separations across various applications, including biopharmaceutical, metabolomics, clinical, environmental, and food testing.
Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis
Phenomenex Inc. has launched its new Luna Omega HILIC LC Columns, designed to improve the separation and retention of highly polar and hydrophilic compounds. These columns are an expansion of the Luna Omega portfolio, offering enhanced method reliability and resolution for various analytical applications including biopharmaceutical and metabolomics. The product aims to simplify HILIC method development while delivering consistent performance, addressing the growing need for sensitive HILIC separations in regulated and high-throughput lab environments.
Danaher Corporation (DHR) Stock Analysis: Unveiling a 32.54% Potential Upside for Investors
Danaher Corporation (DHR), a healthcare sector leader with a market cap of $130.44 billion, is showing a potential upside of 32.54% according to analyst ratings. Its stock, currently priced at $184.30, is near its 52-week low, possibly indicating an attractive entry point. The company boasts strong profitability with an EPS of 5.16, a respectable ROE of 7.08%, and a healthy free cash flow, alongside a positive analyst outlook and a dividend yield of 0.87%.
HR TODAY Honors Danaher India for Innovative Talent Attraction Strategy at Cepheid India
HR TODAY has awarded Danaher India the Excellence in Talent Attraction Award for its innovative "Hire-to-Engage" strategy implemented at Cepheid India. This strategy, comprising Sourcing Excellence, Talent Communities, and Employer Branding, has resulted in single-digit offer drop-out rates and high candidate satisfaction, strengthening Danaher India's reputation as a top MedTech R&D employer. The recognition highlights the importance of strategic talent attraction in achieving business outcomes and setting new benchmarks in the healthcare technology and life sciences sectors.
Why Wall Street Sees Danaher (DHR) Benefiting From Improving Industry Conditions
Wall Street analysts from Citi and RBC Capital are optimistic about Danaher Corporation (DHR) due to improving conditions in the bioprocessing market. Both firms have resumed coverage with Buy/Outperform ratings, citing Danaher's reaffirmed growth guidance and sustained demand across its life sciences portfolio. Analysts believe that a rebound in bioprocessing activity and easing headwinds could help Danaher achieve its targeted 6% revenue growth rate by 2027.
Danaher (DHR) Q1 2026 Earnings Call Transcript
This article provides the Q1 2026 earnings call transcript for Danaher (DHR), powered by Quartr. It details the company participants involved in the call.
Azenta names Trey Martin president of Multiomics business By Investing.com
Azenta, Inc. has appointed Trey Martin as President of its Multiomics business, effective April 6, 2026, to lead the next phase of its multiomics strategy. Martin brings over 30 years of leadership experience in life sciences and previously served as CEO of Maravai Life Sciences and held senior roles at Danaher Corporation. The appointment follows Azenta's Investor Day plans to scale global synthesis capabilities and drive growth.
Danaher Insiders Sold US$235m Of Shares Suggesting Hesitancy
Over the past year, Danaher Corporation (NYSE:DHR) insiders sold US$235 million worth of shares, suggesting some hesitancy among them. The largest single sale was by Co-Founder & Director Mitchell Rales, who sold US$130 million worth of shares at a price higher than the current market price. While insiders own a significant 11% of the company, there have been no insider purchases in the last year, prompting shareholders to investigate further.
Natixis Advisors LLC Acquires 168,917 Shares of Fortive Corporation $FTV
Natixis Advisors LLC significantly increased its stake in Fortive Corporation by 76.6% in the fourth quarter, acquiring an additional 168,917 shares, bringing its total holdings to 389,367 shares valued at $21.5 million. This comes as Fortive reported stronger-than-expected quarterly earnings and revenue and announced a 20 million-share buyback program. Despite these positive developments, Wall Street analysts maintain a cautious "Hold" rating on the stock with an average target price of $61.62.
Reassessing Danaher (DHR) Valuation After Mixed Share Performance And Conflicting Undervaluation Signals
Danaher (DHR) is currently under investor scrutiny due to its mixed stock performance, including a 20.01% decline year-to-date while showing modest gains in the last month. Despite an apparent 17.43% intrinsic discount and a 32.54% gap to analyst targets suggesting undervaluation, its P/E ratio of 35.5x is above the fair ratio of 29.2x. The article highlights the split sentiment between risk and opportunity, urging investors to conduct their own analysis on Danaher's future prospects, especially concerning bioprocess demand and Asian healthcare spending.
IDBS i3 2026 forum in Boston showcases real-world customer outcomes in data-driven BioPharma
IDBS recently held its i3 2026 customer and partner forum in Boston, where BioPharma organizations presented real-world outcomes achieved using IDBS's cloud software. The forum highlighted the importance of structured, contextualized, and trusted data as a foundation for scaling science, automation, and reliable AI execution. Customers shared how they transformed complex workflows and regulatory constraints into practical systems, leading to faster workflows, stronger compliance, and improved data integrity with the IDBS Polar platform.
Danaher Corp. stock outperforms competitors despite losses on the day
Shares of Danaher Corp. (DHR) fell 1.25% to $184.30, breaking a two-day winning streak, during a generally poor trading session for the stock market. Despite the decline, the stock still outperformed the S&P 500 Index and Dow Jones Industrial Average, which experienced larger losses.
Danaher (DHR) Initiated with a Buy at DZ BANK AG
DZ BANK AG has initiated coverage on Danaher (DHR) with a Buy rating and a $210.00 price target. This positive rating follows a recent Buy rating from HSBC, although William Blair assigned a Hold rating earlier. The article notes Danaher's latest quarterly revenue of $5.95 billion and net profit of $1.03 billion, along with recent insider selling activity.
What is multiomics? A simple guide to the future of biology
Multiomics is an ambitious discipline that integrates various biological layers like genomics, transcriptomics, proteomics, and epigenomics to provide a comprehensive understanding of biological processes, health, and disease. This approach allows researchers to move beyond simple correlations to identify causation, offering deeper insights than any single -omic study alone. Illumina supports multiomic research through its platforms and analytical tools, highlighting its potential to vastly improve drug discovery, diagnostics, and precision medicine.
Danaher Corp. stock outperforms competitors on strong trading day
Danaher Corp. (DHR) stock rose 4.81% to $186.64 on a strong trading day, outperforming the S&P 500 Index and the Dow Jones Industrial Average. This marks the stock's second consecutive day of gains.
West Pharma Appoints Former Thermo Fisher Executive Michel Lagarde as CEO
West Pharmaceutical has appointed Michel Lagarde, former chief operating officer at Thermo Fisher Scientific, as its new CEO, effective August 31. Lagarde succeeds Eric Green, who led the medical equipment maker since 2015. Analysts view Lagarde's appointment favorably, and he will also join West Pharma's board.
Jim Cramer on Danaher: “At These Prices, It’s Clearly Overvalued”
Jim Cramer has stated that Danaher Corporation (NYSE: DHR) is currently overvalued, trading at 21 times earnings with only 4-6% organic growth. He contrasted this with Thermo Fisher, which trades at under 20 times earnings and has a 1% organic growth rate. Cramer noted Danaher's stock has been "pulverized" after a series of disappointing quarters, with the stock down 27% year-to-date, alongside other medical and diagnostic companies experiencing significant declines.
Jim Cramer on Danaher: “At These Prices, It’s Clearly Overvalued”
Jim Cramer has stated that Danaher Corporation (NYSE: DHR) is "clearly overvalued" at its current stock prices, citing its low organic growth rate of 4-6% compared to its 21 times earnings valuation. He noted that the company's stock has been "pulverized" after a series of disappointing quarters, with a 27% year-to-date decline. Cramer also highlighted that competitors like Thermo Fisher trade at a lower earnings multiple with similar or lower organic growth prospects.
Dh Masi Finance Inc. Enters into Note Purchase and Guaranty Agreement for Issuance of CHF 2,382,280,000 Senior Notes Guaranteed by Danaher Corporation
Dh Masi Finance Inc., a wholly-owned subsidiary of Danaher Corporation, has entered into a note purchase and guaranty agreement for the issuance and sale of CHF 2,382,280,000 in aggregate principal amount of senior notes across seven series. These notes, maturing between 2031 and 2056 with fixed interest rates ranging from 1.65% to 2.51%, are unsecured obligations of Dh Masi Finance Inc. but are fully and unconditionally guaranteed by Danaher Corporation. The net proceeds are intended for general corporate purposes, including working capital, acquisitions, and share repurchases.
Danaher (NYSE: DHR) issues long-dated CHF senior notes for general purposes
Danaher Corporation, through its subsidiary DH Masi Finance Inc., has issued multiple series of Swiss franc-denominated senior notes totaling over CHF 2.47 billion in a private placement. These long-dated notes mature between 2031 and 2056 with fixed interest rates ranging from 1.65% to 2.51%. The net proceeds from these unsecured obligations, which are fully guaranteed by Danaher, are intended for general corporate purposes, including working capital, acquisitions, and share repurchases.
Danaher Corp. stock outperforms competitors on strong trading day
Shares of Danaher Corp. (DHR) rose by 1.12% to $178.08 on Wednesday, defying a generally grim trading day for the broader stock market. The S&P 500 Index (SPX) fell 0.74%, and the Dow Jones Industrial Average (DJIA) fell 1.21%. This increase for Danaher Corp. ended a two-day losing streak for the stock.
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
Leica Biosystems is expanding its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry (IHC) assay and an AI-powered image analysis algorithm for the TROP2 Normalized Membrane Ratio (NMR) biomarker in non-small cell lung cancer. This partnership aims to create an end-to-end solution for assessing this novel biomarker, leveraging Leica Biosystems' digital pathology solutions and AstraZeneca's computational pathology algorithm. The initiative seeks to advance precision medicine by identifying patients who would most benefit from targeted therapies.
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
Leica Biosystems has expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry (IHC) assay and an AI-powered image analysis algorithm for the TROP2 Normalized Membrane Ratio (NMR) biomarker in non-small cell lung cancer. This partnership aims to create an end-to-end solution for assessing this novel biomarker, leveraging Leica Biosystems' digital pathology solutions and AstraZeneca's computational pathology algorithm (QCS). The goal is to advance precision medicine by identifying patients most likely to benefit from targeted therapies through AI-assisted diagnostics, deploying the algorithm via the Aperio AI Store.
What Danaher (DHR)'s New AI-Enabled SCIEX Mass Spec Platform Means For Shareholders
Danaher's SCIEX unit has launched new AI-enabled mass spectrometry platforms, enhancing its presence in data-intensive life science research. These upgrades, including the ZenoTOF line and novus V55 triple quadrupole mass spectrometer with SCIEX OS 5.0 software, aim to drive recurring revenue through consumables and service contracts by expanding the installed base of advanced instruments. While reinforcing Danaher's innovation narrative, investors should consider potential margin pressure from rising R&D investments if adoption is slow.
Danaher Corp. stock outperforms competitors despite losses on the day
Danaher Corp. (DHR) shares fell by 2.09% on Tuesday, closing at $176.11, despite a positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains. This marks the second consecutive day of losses for Danaher's stock.
Danaher Corp. stock (US2358511028): Wolfe Research starts coverage as shares trade lower
Wolfe Research has initiated coverage on Danaher Corp. (DHR) with a "Peer Perform" rating, as the stock traded lower on the NYSE. The initiation comes as Danaher reported adjusted earnings per share of $2.06 and declared a quarterly dividend of $0.40 per share for its latest quarter, exceeding market expectations. The article highlights how new analyst opinions can coincide with short-term volatility for blue-chip stocks.
DHR Assumed by Wolfe Research -- Rating Set to Peer Perform
Wolfe Research has initiated coverage on Danaher (DHR) with a "Peer Perform" rating. This follows mixed analyst sentiment, including a recent downgrade from Citigroup and a reinstatement by RBC Capital. Despite these varied opinions, GuruFocus data indicates DHR is approximately 23.8% undervalued with strong fundamentals, suggesting potential for steady performance for investors.
Wolfe Research initiates Danaher stock coverage with Peerperform rating
Wolfe Research has initiated coverage on Danaher Corp. (NYSE:DHR) with a Peerperform rating, setting a fair value range of $165 to $185 per share. Their valuation model incorporates the upcoming $10 billion Masimo acquisition, expected to close on July 1, impacting 2026 earnings and showing full accretion in 2027. Despite a current P/E of 34.93, InvestingPro suggests the stock is undervalued, and Wolfe Research notes its valuation represents a discount to the S&P 500 multiple.
Wolfe Research initiates Danaher stock coverage with Peerperform rating By Investing.com
Wolfe Research initiated coverage on Danaher Corp. (NYSE:DHR) with a Peerperform rating, setting a fair value range of $165 to $185 per share, which is around the current trading price. The valuation is based on an 18 to 20 times 2027 earnings per share estimate, incorporating the upcoming Masimo acquisition. The firm notes that Danaher, a prominent player in the Life Sciences Tools & Services industry, has a "GOOD" financial health score according to InvestingPro metrics.
Wolfe Research initiates Danaher stock coverage with Peerperform rating
Wolfe Research has initiated coverage on Danaher Corp. (NYSE:DHR) with a Peerperform rating and a fair value range of $165 to $185 per share. The valuation incorporates the upcoming Masimo acquisition, expected to close on July 1, and projects a 15 to 20 cents first-year accretion in 2027. Danaher, with a market cap of $127.6 billion, maintains a "GOOD" financial health score, and its stock currently trades within the firm's target range.
Danaher Corp. stock (US2358511028): shares ease while investors digest product updates and analyst b
Danaher Corp. shares experienced a modest decline on the NYSE, trading around USD 180 as investors considered recent product launches in its life-science tools portfolio and the overall analyst outlook. The company's SCIEX operating unit introduced the novus V55 system, a new mass spectrometer designed to enhance throughput and reduce operating costs for labs. Despite the slight share price movement, Danaher continues to innovate its product pipeline and maintain an active investor relations presence, focusing on recurring-revenue tools and consumables.
Dominion Energy Inc stock (US2358511028): shares ease after recent ex-dividend date
Dominion Energy Inc. shares traded lower on the NYSE on June 1, 2026, after going ex-dividend on May 29, 2026, leading investors to re-evaluate the utility's income profile. The stock's intraday trading range was between USD 65.09 and USD 66.43, with a market capitalization of approximately USD 57.3 billion and a P/E ratio near 19.3. Despite the dip, technical analysis suggests the broader medium-term uptrend for the US power and gas group remains intact, anchoring its valuation in the US regulated-utility peer group.
Avoiding Lag: Real-Time Signals in (DHR) Movement
This article analyzes Danaher Corporation (DHR) movement, noting strong near and mid-term sentiment that could extend long-term. It identifies a mid-channel oscillation pattern and an exceptional risk-reward setup targeting a 13.1% gain versus 0.3% risk. The article provides specific AI-generated trading strategies (Position Trading, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses.
SCIEX unveils 1-sample-per-second mass spec to speed early discovery
SCIEX, a Danaher company, has introduced significant advancements to its ZenoTOF mass spectrometry platform, including new SCIEX OS 5.0 software features, enhanced front-end compatibility, and key collaborations. These updates aim to reduce workflow complexity and provide deeper insights for omics researchers, notably enabling high-throughput screening at up to one sample per second with improved sensitivity. The platform expansions are designed to accelerate early discovery, expand proteomics and metabolomics applications, and integrate seamlessly with existing research workflows.
Danaher Corp. stock underperforms Monday when compared to competitors
Danaher Corp. (DHR) stock fell by 1.53% on Monday, closing at $179.87, despite a positive trading session for the broader market. This drop ended a four-day winning streak for the company's shares. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains on the same day.
[8-K] HONEYWELL INTERNATIONAL INC Reports Material Event
Honeywell International Inc. (HON) announced the appointment of Jillian (Jill) Evanko, CEO of Duravant LLC, to its Board of Directors as an Independent Director and Audit Committee member, effective June 1, 2026. Evanko brings over 25 years of industrial and manufacturing experience and will stand for election at the 2027 Annual Meeting of Shareowners. She is also anticipated to continue on the Honeywell board after the planned spin-off of its Aerospace business on June 29, 2026.
IDT partners with Illumina on oncology research workflow
Integrated DNA Technologies (IDT), a Danaher company, has announced a collaboration with Illumina Inc. to integrate IDT’s library preparation solutions with Illumina’s DRAGEN secondary analysis platform for oncology research. This partnership aims to streamline genomic data analysis, especially for degraded tissue samples, and enhance compatibility with Illumina Connected Insights. Illumina's shares have seen a significant increase over the past year, reflecting market confidence despite some analyst revisions.
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
Integrated DNA Technologies (IDT) and Illumina have collaborated to create an end-to-end somatic oncology research solution. This partnership integrates IDT’s xGen FFPE and cfDNA library preparation workflows with Illumina's DRAGEN secondary analysis platform, aiming to streamline data processing and accelerate insights from challenging samples. The new workflow, including a low-quality FFPE mode, is designed to enhance variant detection and improve the reliability of results for oncology researchers.
Avantor (AVTR) Appoints Ludovic Brellier as EVP and Chief Transformation Officer
Avantor Inc. (NYSE: AVTR) has appointed Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products/BMP and Chief Transformation Officer, effective May 1st. In this dual role, Brellier will manage the BMP business growth and operational performance, while also leading the company's enterprise-wide transformation initiative. Brellier previously held leadership roles at Danaher's Cytiva, and his expertise is expected to be crucial for Avantor's strategic initiatives and long-term sustainable growth.
Phenomenex Launches Endrix Long Life Columns, Redefining Column Durability and Method Reliability
Phenomenex Inc. has launched Endrix Long Life LC columns, a new liquid chromatography solution designed to offer extended column lifespan and consistent performance for demanding analytical workflows. These columns are engineered to withstand challenging sample matrices and rigorous method conditions, aiming to reduce downtime and improve throughput for laboratories. The product is particularly suitable for pharmaceutical, clinical, forensic, toxicology, environmental, and food testing laboratories, and will be officially unveiled at the 73rd ASMS Conference.
